{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:49:59Z","timestamp":1794473399620,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03916-y","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T10:20:58Z","timestamp":1748600458000},"page":"3293-3306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025)"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-362X","authenticated-orcid":false,"given":"Teresa","family":"Macarulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Adeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Cano Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ruiz Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Jim\u00e9nez Gordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"L\u00f3pez Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Antonio","family":"Pazo Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Saur\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gallego Plazas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"4","key":"3916_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.gastha.2022.04.007","volume":"1","author":"K Baria","year":"2022","unstructured":"Baria K, De Toni EN, Yu B, Jiang Z, Kabadi SM, Malvezzi M. Worldwide incidence and mortality of biliary tract cancer. Gastro Hep Adv. 2022;1(4):618\u201326.","journal-title":"Gastro Hep Adv"},{"key":"3916_CR2","unstructured":"- Las cifras del c\u00e1ncer en Espa\u00f1a 2024. SEOM"},{"issue":"5","key":"3916_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","volume":"21","author":"SK Saha","year":"2016","unstructured":"Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594\u20139.","journal-title":"Oncologist"},{"key":"3916_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ejca.2022.08.032","volume":"175","author":"R Rahman","year":"2022","unstructured":"Rahman R, Ludvigsson JF, von Seth E, Lagergren J, Bergquist A, Radkiewicz C. Age trends in biliary tract cancer incidence by anatomical subtype: a Swedish cohort study. Eur J Cancer. 2022;175:291\u20138.","journal-title":"Eur J Cancer"},{"issue":"6","key":"3916_CR5","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022;77(6):1690\u20138.","journal-title":"J Hepatol"},{"issue":"3","key":"3916_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100983","volume":"6","author":"D Tataru","year":"2024","unstructured":"Tataru D, Khan SA, Hill R, Morement H, Wong K, Paley L, et al. Cholangiocarcinoma across England: temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation. JHEP Rep. 2024;6(3): 100983.","journal-title":"JHEP Rep"},{"issue":"2","key":"3916_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley RK, Kl\u00fcmpen HJ, Malka D, et al. Biliary tract cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.","journal-title":"Ann Oncol"},{"key":"3916_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102258","volume":"99","author":"J Edeline","year":"2021","unstructured":"Edeline J, Lamarca A, McNamara MG, Jacobs T, Hubner RA, Palmer D, et al. Locoregional therapies in patients with intrahepatic cholangiocarcinoma: a systematic review and pooled analysis. Cancer Treat Rev. 2021;99: 102258.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3916_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.gie.2013.12.031","volume":"80","author":"F Weilert","year":"2014","unstructured":"Weilert F, Bhat YM, Binmoeller KF, Kane S, Jaffe IM, Shaw RE, et al. EUS-FNA is superior to ERCPbased tissue sampling in suspected malignant biliary obstruction: results of a prospective, single-blind, comparative study. Gastrointest Endosc. 2014;80(1):97\u2013104.","journal-title":"Gastrointest Endosc"},{"issue":"1017","key":"3916_CR10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1259\/bjr\/88405305","volume":"85","author":"AT Ruys","year":"2012","unstructured":"Ruys AT, van Beem E, Engelbrecgt MRW, Bipat S, Stoker J, Van Gulik TM. Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol. 2012;85(1017):1255\u201362.","journal-title":"Br J Radiol"},{"key":"3916_CR11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.clinimag.2020.10.056","volume":"71","author":"P Guniganti","year":"2021","unstructured":"Guniganti P, Kierans AS. PET\/\/ MRI of the hepatobiliary system: review of techniques and applications. Clin Imaging. 2021;71:160\u20139.","journal-title":"Clin Imaging"},{"key":"3916_CR12","volume-title":"UICC TNM classification of malignant tumours","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C, editors. UICC TNM classification of malignant tumours. 8Th ed. Oxford, UK: Wiley-Blackwell; 2017.","edition":"8Th"},{"issue":"2","key":"3916_CR13","first-page":"170","volume":"140","author":"H Bismuth","year":"1975","unstructured":"Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet. 1975;140(2):170\u20138.","journal-title":"Surg Gynecol Obstet"},{"issue":"10272","key":"3916_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"key":"3916_CR15","volume":"190","author":"T Demir","year":"2024","unstructured":"Demir T, Moloney C, Mahalingam D. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers. Crit Rev Oncol\/\/ Hematol. 2024;190: 103178.","journal-title":"Crit Rev Oncol\/\/ Hematol"},{"key":"3916_CR16","first-page":"189","volume":"69","author":"European Association for the Study of the Liver","year":"2023","unstructured":"European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;69:189\u2013236.","journal-title":"J Hepatol"},{"key":"3916_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104388","volume":"199","author":"T Demir","year":"2024","unstructured":"Demir T, Moloney C, Mahalingam D. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers. Crit Rev Oncol Hematol. 2024;199: 104388.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3916_CR18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"44","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;44:1853\u201365.","journal-title":"Lancet Oncol"},{"key":"3916_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3916_CR20","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u201377.","journal-title":"JAMA Oncol"},{"issue":"4","key":"3916_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/13543784.2021.1854724","volume":"30","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Bonucci C, Tober N, Palloni A, Frega G, et al. Experimental HER2- targeted therapies for biliary tract cancer. Expert Opin Investig Drugs. 2021;30(4):389\u201399.","journal-title":"Expert Opin Investig Drugs"},{"key":"3916_CR22","volume-title":"AJCC cancer staging manual","author":"MB Amin","year":"2017","unstructured":"Amin MB, Edge S, Greene F, Schilsky R, Gaspar L, Washington M, et al. AJCC cancer staging manual. 8th ed. New York. NY: Springer; 2017.","edition":"8"},{"issue":"9","key":"3916_CR23","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.2012.41.5984","volume":"31","author":"Y Wang","year":"2013","unstructured":"Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188\u201395. https:\/\/doi.org\/10.1200\/JCO.2012.41.5984. (Epub 2013 Jan 28 PMID: 23358969).","journal-title":"J Clin Oncol"},{"issue":"2","key":"3916_CR24","doi-asserted-by":"publisher","first-page":"254","DOI":"10.14218\/JCTH.2021.00099","volume":"10","author":"SN Zhou","year":"2022","unstructured":"Zhou SN, Lu SS, Ju DW, Yu LX, Liang XX, Xiang X, et al. A new prognostic model covering all stages of intrahepatic cholangiocarcinoma. J Clin Transl Hepatol. 2022;10(2):254\u201362. https:\/\/doi.org\/10.14218\/JCTH.2021.00099. (Epub 2021 Jul 7. PMID: 35528972; PMCID: PMC9039701).","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"3916_CR25","doi-asserted-by":"publisher","first-page":"10206","DOI":"10.1038\/s41598-022-13605-3","volume":"12","author":"MJ Kang","year":"2022","unstructured":"Kang MJ, Lim J, Han SS, Park HM, Kim SW, Lee WJ, et al. Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep. 2022;12(1):10206. https:\/\/doi.org\/10.1038\/s41598-022-13605-3. (PMID:35715440;PMCID:PMC9205970).","journal-title":"Sci Rep"},{"issue":"23","key":"3916_CR26","doi-asserted-by":"publisher","first-page":"744","DOI":"10.21037\/atm.2019.12.37","volume":"7","author":"H Hang","year":"2019","unstructured":"Hang H, Jeong S, Sha M, Kong D, Xi Z, Tong Y, et al. Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities. Ann Transl Med. 2019;7(23):744. https:\/\/doi.org\/10.21037\/atm.2019.12.37. (PMID:32042760;PMCID:PMC6989985).","journal-title":"Ann Transl Med"},{"issue":"5","key":"3916_CR27","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Kl\u00fcmpen HJ, et al. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.010. (Epub 2022 Feb 12 PMID: 35167909).","journal-title":"J Hepatol"},{"issue":"1","key":"3916_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/annonc\/mdv483","volume":"27","author":"J Bridgewater","year":"2016","unstructured":"Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27(1):134\u201340.","journal-title":"Ann Oncol"},{"issue":"8","key":"3916_CR29","first-page":"1669","volume":"71","author":"RIR Macias","year":"2022","unstructured":"Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, et al. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut. 2022;71(8):1669\u201383.","journal-title":"Gut"},{"issue":"24","key":"3916_CR30","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1200\/JCO.21.02576","volume":"40","author":"AJ Scott","year":"2022","unstructured":"Scott AJ, Sharman R, Shroff RT. Precision medicine in biliary tract cancer. J Clin Oncol. 2022;40(24):2716\u201334.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3916_CR31","doi-asserted-by":"publisher","first-page":"7119","DOI":"10.1038\/s41598-018-25669-1","volume":"8","author":"M Simbolo","year":"2018","unstructured":"Simbolo M, Vicentini C, Ruzzenente A, Brunelli M, Conci S, Fassan M, et al. Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Sci Rep. 2018;8(1):7119.","journal-title":"Sci Rep"},{"issue":"6","key":"3916_CR32","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","volume":"68","author":"M Li","year":"2019","unstructured":"Li M, Liu F, Zhang F, Zhou W, Jiang X, Yang Y, et al. Genomic ERBB2\/\/ ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut. 2019;68(6):1024\u201333.","journal-title":"Gut"},{"issue":"5","key":"3916_CR33","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s12094-021-02573-1","volume":"23","author":"MA G\u00f3mez-Espa\u00f1a","year":"2021","unstructured":"G\u00f3mez-Espa\u00f1a MA, Montes AF, Garcia-Carbonero R, Mercad\u00e9 TM, Maurel J, Mart\u00edn AM, Pazo-Cid R, et al. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). Clin Transl Oncol. 2021;23(5):988\u20131000.","journal-title":"Clin Transl Oncol"},{"issue":"8","key":"3916_CR34","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190\u20138.","journal-title":"Int J Cancer"},{"issue":"1","key":"3916_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/\/ mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310.","journal-title":"J Clin Oncol"},{"key":"3916_CR36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ctrv.2018.09.002","volume":"70","author":"A Lamarca","year":"2018","unstructured":"Lamarca A, Barriuso J, McNamara MG, Valle JW. Biliary tract cancer: state of the art and potential role of DNA damage repair. Cancer Treat Rev. 2018;70:168\u201377.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"3916_CR37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/bjs.10776","volume":"105","author":"T Ebata","year":"2018","unstructured":"Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105(3):192\u2013202.","journal-title":"Br J Surg"},{"issue":"8","key":"3916_CR38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly J-P, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658\u201367.","journal-title":"J Clin Oncol"},{"issue":"18","key":"3916_CR39","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1200\/JCO.21.02568","volume":"40","author":"J Bridgewater","year":"2022","unstructured":"Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40(18):2048\u201357.","journal-title":"J Clin Oncol"},{"issue":"Suppl_16","key":"3916_CR40","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1200\/JCO.2024.42.16_suppl.4119","volume":"42","author":"K Nakachi","year":"2024","unstructured":"Nakachi K, Ikeda M, Konishi M, Mizusawa J, Katayama H, Sano Y, et al. Adjuvant S-1 vs observation for resected biliary tract cancer: 5-year follow-up of the JCOG1202\/\/ ASCOT. J Clin Oncol. 2024;42(Suppl_16):4119.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3916_CR41","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","volume":"77","author":"H Jeong","year":"2023","unstructured":"Jeong H, Kim KP, Jeong JH, Hwang DW, Lee JH, Kim KH, et al. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology. 2023;77(5):1540\u20139.","journal-title":"Hepatology"},{"issue":"24","key":"3916_CR42","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless ChL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic chol- angiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3916_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced Intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):51\u20139.","journal-title":"JAMA Oncol"},{"issue":"14","key":"3916_CR44","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"9","key":"3916_CR45","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol Off J Eur Soc Med Oncol. 2004;15(9):1339\u201343.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"3916_CR46","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3916_CR47","doi-asserted-by":"publisher","first-page":"S1462","DOI":"10.1016\/j.annonc.2022.10.114","volume":"33","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol. 2022;33:S1462\u20133.","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"3916_CR48","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1200\/JCO.2024.42.16_suppl.4093","volume":"42","author":"RS Finn","year":"2024","unstructured":"Finn RS, Ueno M, Yoo C, Ren Z, Furuse J, Kelley RK, et al. Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/\/ cis) compared with gem\/\/ cis alone for patients (pts) with advanced biliary tract cancer (BTC). J Clin Oncol. 2024;42(16_suppl):4093\u20134093.","journal-title":"J Clin Oncol"},{"issue":"S1","key":"3916_CR49","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.annonc.2024.05.285","volume":"35","author":"D-Y Oh","year":"2024","unstructured":"Oh D-Y, He AR, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in biliary tract cancer (BTC). Ann Oncol. 2024;35(S1):S117.","journal-title":"Ann Oncol"},{"key":"3916_CR50","doi-asserted-by":"publisher","first-page":"S1457","DOI":"10.1016\/j.annonc.2022.10.104","volume":"33","author":"JW Valle","year":"2022","unstructured":"Valle JW, Qin S, Antonuzzo L, Tougeron D, Lee CK, Tan BJ, et al. 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC). Ann Oncol. 2022;33:S1457.","journal-title":"Ann Oncol"},{"issue":"5","key":"3916_CR51","first-page":"914","volume":"39","author":"N Schweitzer","year":"2019","unstructured":"Schweitzer N, Kirstein MM, Kratzel AM, Mederacke YS, Fischer M, Manns MP, et al. Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors. Liver Int Off J Int Assoc Study Liver. 2019;39(5):914\u201323.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"5","key":"3916_CR52","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3916_CR53","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","volume":"22","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim KP, Jeong JH, Kim I, Kang MJ, Cheon J, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021;22(11):1560\u201372.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3916_CR54","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S2468-1253(24)00119-5","volume":"9","author":"A Vogel","year":"2024","unstructured":"Vogel A, Saborowski A, Wenzel P, Wege H, Folprecht G, Kretzschmar A, et al. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9(8):734\u201344.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"3916_CR55","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41416-018-0138-2","volume":"119","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Tu X, Zhao P, Jiang W, Liu L, Tong Z, et al. A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin. Br J Cancer. 2018;119(3):291\u20135.","journal-title":"Br J Cancer"},{"issue":"154","key":"3916_CR56","first-page":"288","volume":"2021","author":"IS Choi","year":"1990","unstructured":"Choi IS, Kim KH, Lee JH, Suh KJ, Kim JW, Park JH, et al. A randomised phase II study of oxaliplatin\/\/ 5-FU (mFOLFOX) versus irinotecan\/\/ 5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/\/ cisplatin chemotherapy. Eur J Cancer Oxf Engl. 1990;2021(154):288\u201395.","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"3","key":"3916_CR57","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339.","journal-title":"N Engl J Med"},{"issue":"9","key":"3916_CR58","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","volume":"21","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Lassen U, \u00c9lez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234\u201343.","journal-title":"Lancet Oncol"},{"issue":"9","key":"3916_CR59","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290\u2013300.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3916_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the Destiny-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3916_CR61","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24(7):772\u201382.","journal-title":"Lancet Oncol"},{"issue":"9","key":"3916_CR62","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929\u201338.","journal-title":"Ann Oncol"},{"issue":"7","key":"3916_CR63","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(7):1302\u201312.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"8","key":"3916_CR64","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"3916_CR65","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/\/ 2, open-label, basket trial. Lancet Oncol. 2022;23(10):1261\u201373.","journal-title":"Lancet Oncol"},{"issue":"9","key":"3916_CR66","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol. 2018;29(9):1895\u2013902.","journal-title":"Ann Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03916-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03916-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03916-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:22:48Z","timestamp":1757175768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03916-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":66,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["3916"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03916-y","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TMM reports Advisory Board from Ability PhaAbility Pharmaceuticals SL, Arcus Bioscience Inc, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Incyte, Ipsen Bioscience Inc, MSD and Novocure rmaceuticals SL; Speaker from Janssen, Lilly, Esteve, Da\u00efchi, Biontech, Novartis, Jazz Pharmaceuticals steve, Da\u00efchi, Biontech, Novartis and Jazz Pharmaceuticals; Grant from MSD, Novocure, QED Therapeutics, Roche Farma, Sanofi-Aventis, Servier and Zymeworks and Other from Servier, AstraZeneca, Sanofi, Incyte, Lilly, MSD and Roche. JAA reports Advisory Board from Servier, Incyte, Taio and AstraZeneca; Speaker from Incyte and AstraZeneca and Other from Merck and Servier. ARC reports Advisory Board from Amgen and Takeda; Speaker from Medtronic and Other from Servier. RAPC reports Advisory Board\u2014Speaker\u2014Other from Servier, Roche and AstraZeneca; Advisory Board from Ipsen; Advisory Board\u2014Speaker from Astellas and Eisai and Speaker from Lilly. TSN reports Speaker from BMS, MSD, AstraZeneca, Astellas and Jazz Pharmaceuticals and Advisory Board from Amgen and Beigene Esp. SLU. MTCO, AMJG, ALL, AMLM, JG have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Compliance with ethical standards. The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}